There are currently 41 ongoing clinical trials involving Colitis
Of the 41 trials,20 trials are in Phase II
Furthermore, 7 trials are in Phase IV
The global pharmaceutical industry is steadily developing new drugs for Colitis, a Gastrointestinal indication. The largest number of ongoing clinical trials for Colitis is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions involved in Colitis-related drug trials.
Johnson & Johnson: The leading ongoing Colitis-related clinical trial sponsor
Johnson & Johnson, the US-based pharmaceuticals company, is the top sponsor for Colitis-related ongoing clinical trials.
University of Texas MD Anderson Cancer Center, Bristol-Myers Squibb Co, Memorial Sloan Kettering Cancer Center, Cambridge University Hospitals NHS Foundation Trust, and Jewish General Hospital are a few other notable sponsors involved in Colitis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Colitis
Rifaximin (Xifaxan/ Normix/ Spiraxin/ Normiks/ Refero/ Targaxan/ Tixteller/ Zaxine/ Faxinorm/ Xifaxanta/ Redactiv/ Tixtar/ Rifacol/ Rifxima),Methylprednisolone (Solu-Medrol, Depo-Medrol, Medrol, Medrate, Depo-Medrate, Medrol Acetate, Solu-Medrone, Solu-Moderin, Depo-Medrone, Methylprednisolone Sodium Succinate, Promedrol, Medrol A, Medroxyprogesterone Acetate Greenstone), and Mesalamine (Asacol, Asacol HD-, Octasa, Yaldigo, Mesalamine Zydus, Mesalamine Zeria, Asazine, Lixacol) are among the key marketed drugs involving Colitis.
Rifaximin (Xifaxan/ Normix/ Spiraxin/ Normiks/ Refero/ Targaxan/ Tixteller/ Zaxine/ Faxinorm/ Xifaxanta/ Redactiv/ Tixtar/ Rifacol/ Rifxima) is a non-aminoglycoside semi-synthetic antibiotic acts as anti-bacterial agent. It functions via the DNA Directed RNA Polymerase (POLR2 or EC 2.7.7.6) Inhibitor mechanism of action. It is formulated as tablets, film-coated tablets, and granules for oral route of administration and ointment and cream for topical application. Rafle is indicated for the treatment of patients with travellers’diarrhoea (TD) caused by noninvasive strains of Escherichia coli and reduction in risk of overt hepatic encephalopathy. Rifaximin was first approved in 1985 and is marketed globally including the US, the UK, France, Germany, China, and Japan by Salix Pharmaceuticals Inc.
Methylprednisolone (Solu-Medrol, Depo-Medrol, Medrol, Medrate, Depo-Medrate, Medrol Acetate, Solu-Medrone, Solu-Moderin, Depo-Medrone, Methylprednisolone Sodium Succinate, Promedrol, Medrol A, Medroxyprogesterone Acetate Greenstone) is a glucocorticoid, anti-inflammatory agent. It functions via Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist mechanism of action It is formulated as tablets for oral administration, lyophilized powder for solution, suspension and solution for intravenous, intramuscular, intraarticular, intralesional, intrasynovial route of administration. It is also formulated as enema for rectal administration and as ointment for topical administration. It is indicated in the treatment of encephalitis, optic neuritis, lupus erythematosus, allergic bronchitis, acquired (autoimmune) hemolytic anemia, pulmonary fibrosis, meningitis, hypoglycemia, rheumatoid arthritis, juvenile rheumatoid arthritis, polymyalgia rheumatica, uveitis, chorioretinitis, blepharitis, conjunctivitis, keratitis, scleritis, eczema, asthma, atopic dermatitis. Methylprednisolone was first approved in 1957 and is marketed globally including the US, the UK, France, Germany, China, and Japan by Pfizer Inc.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer